.png)
.png)
Latest news from BIA
BIA response to UK government’s plans for free trade deals and tariff plans
Steve Bates OBE, Chief Executive of the BioIndustry Association said: “For the UK life sciences sector to understand the benefit of any free trade deal we need to see the granular detail of what the UK hopes to achieve. Strengthening Intellectual Property regimes globally would benefit innovative UK life sciences businesses, so it is positive to see the Government recognises the importance of this issue in planning a US FTA.”
BIA welcomes publication of the Life Sciences 2030 Skills Strategy
The UK BioIndustry Association (BIA) has welcomed today’s publication of the Life Sciences 2030 Skills Strategy. The report is a key deliverable from the Life Sciences Sector Deal 2 and sets out how the UK Life Sciences sector will attract, retain, train and develop the research, manufacturing and technical skills required by a dynamic and diverse UK sector.
UK biotech records third highest year for investment despite global uncertainty
New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019. The total is the third highest year recorded by the trade association and since 2012 investment has increased by over 400%
BIA responds to the newly announced NHS England/Novartis deal
Commenting on the new NHS England/Novartis deal and the publication of the new UK life sciences sector update announced at JP Morgan today, Steve Bates OBE, Chief Executive of the BioIndustry Association said: "Global players are announcing the UK as their destination of choice for innovation at this year’s JP Morgan Healthcare conference.
State of the Market for Directors & Officers Liability Insurance (D&O)
In our State of the Market report published in February 2019, we wrote that we did not expect market conditions to improve for the better in 2019. Unfortunately, that prediction has held, and as we enter into Q1 2020, the Directors’ and Officers’ (D&O) insurance market remains a difficult place in which to do business.
PhoreMost strengthens leadership team with two key appointments
• Dr Catherine Beech, OBE, joins Board as a Non-Executive Director • Dr Benedict Cross joins as Senior Director (Technology)
Press release: New Cell and Gene Therapy Catapult CEO brings continuity and ambition for further impact
Matthew Durdy appointed to CEO role as the CGT Catapult prepares to accelerate innovation, growth and productivity, where needed in the UK.
Mogrify awarded $1.1M additional funding from SBRI Healthcare
• Phase II funding will be used for pre-clinical assessment of regenerative cartilage therapy • Follows Phase I SBRI funding, announced in April 2019
CEO Update|Monday 03 February 2020
The UK officially left the E U last Friday. Today we saw greater clarity from both sides on how they plan to approach the upcoming negotiations about the future relationship. This morning’s speech by Boris Johnson, the Written Ministerial Statement and the new European Commission document authorising the opening of negotiations for a new partnership with the UK, together give an idea of where we might be headed and some of the obstacles to reaching agreement.
BIA on Brexit
Despite the rollercoaster political backdrop since the referendum result the UK biotech sector is heading into the new decade and life outside the EU in a very strong position. As the BIA’s recently launched annual finance report showed, 2019 was the third best year recorded and the fifth consecutive year in which more than £1bn was raised. It’s clear that UK biotech companies remain an attractive investment opportunity for global investors.
Life Sciences Future Skills 2030
As published in the Life Sciences Industrial Strategy update this month, and as a result of strong collaboration across all sectors, there has been substantial progress in making the UK a more attractive place for life sciences companies.
CEO Update | Monday 27 January 2020
The launch of our annual finance report: ‘Global and growing: UK biotech financing in 2019’ was well received by members and the media. The report shows that the UK biotech sector is heading into the new decade in a very strong position. 2019 was the third best year recorded by the BIA and the fifth consecutive year in which more than £1bn was raised. We have seen a drop in investment globally, across all countries and sectors but it’s clear that UK biotech companies remain an attractive investment opportunity for global investors.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector | BIA update: October 2019 - January 2020
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.
Global and growing - UK biotech financing in 2019
New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.
UK life sciences: Catalysing investment and growth
This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.
BIA biotech manifesto 2019
The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.
